Innovent Biologics (HKG:1801) recorded a total product revenue of 2 billion yuan or more in the fourth quarter of 2024, up at least 25% from a year prior, a Thursday bourse filing said.
In full-year 2024, product revenue grew by at least 40% to 8.2 billion yuan.
The drug company attributed the rise in revenue mainly to its leading position in the oncology niche, fast growth of major products, and the strong ramp-up momentum of new products.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。